Cambrex Corp. (NYSE:CBM)’s share price fell 2.7% on Friday . The stock traded as low as $52.18 and last traded at $52.25, with a volume of 411,405 shares trading hands. The stock had previously closed at $53.72.

Separately, Zacks Investment Research raised shares of Cambrex Corp. from a “hold” rating to a “strong-buy” rating and set a $56.00 price objective for the company in a research note on Wednesday, May 4th.

The firm has a market capitalization of $1.77 billion and a price-to-earnings ratio of 26.50. The company has a 50-day moving average price of $52.73 and a 200 day moving average price of $45.37.

Cambrex Corp. (NYSE:CBM) last posted its earnings results on Thursday, July 28th. The company reported $0.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.09. The firm earned $118.22 million during the quarter, compared to analyst estimates of $114.85 million. During the same quarter in the prior year, the firm earned $0.63 earnings per share. The business’s revenue for the quarter was up 10.9% on a year-over-year basis. Equities analysts anticipate that Cambrex Corp. will post $2.57 earnings per share for the current fiscal year.

In related news, CEO Steven M. Klosk sold 16,430 shares of the business’s stock in a transaction on Thursday, May 5th. The shares were sold at an average price of $49.13, for a total value of $807,205.90. Following the completion of the transaction, the chief executive officer now directly owns 136,828 shares in the company, valued at approximately $6,722,359.64. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director William B. Korb sold 3,420 shares of the business’s stock in a transaction on Monday, July 11th. The shares were sold at an average price of $55.00, for a total transaction of $188,100.00. Following the completion of the transaction, the director now owns 23,982 shares of the company’s stock, valued at $1,319,010. The disclosure for this sale can be found here.

A number of institutional investors recently bought and sold shares of the company. Pear Tree Advisors Inc. bought a new position in Cambrex Corp. during the fourth quarter worth $1,008,000. Dimensional Fund Advisors LP boosted its position in Cambrex Corp. by 3.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,589,449 shares of the company’s stock worth $74,848,000 after buying an additional 47,279 shares in the last quarter. Redwood Investments LLC boosted its position in Cambrex Corp. by 28.9% in the fourth quarter. Redwood Investments LLC now owns 45,791 shares of the company’s stock worth $2,156,000 after buying an additional 10,259 shares in the last quarter. Century Capital Management LLC boosted its position in Cambrex Corp. by 13.5% in the fourth quarter. Century Capital Management LLC now owns 353,591 shares of the company’s stock worth $16,651,000 after buying an additional 42,189 shares in the last quarter. Finally, Victory Capital Management Inc. boosted its position in Cambrex Corp. by 13,241.1% in the fourth quarter. Victory Capital Management Inc. now owns 142,483 shares of the company’s stock worth $6,710,000 after buying an additional 141,415 shares in the last quarter.

Cambrex Corporation (Cambrex) is a life sciences company. The Company provides products and services for the development and commercialization of new and generic therapeutics. The Company supplies its products and services across the world to generic pharmaceutical companies. Cambrex operates through three segments, which are manufacturing facilities.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.